Drugs / Arlocabtagene Autoleucel
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06121843 | Feb 2024 → Aug 2028 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 1 | NCT04674813 | Feb 2021 → Dec 2025 | plasma cell myeloma | Juno Therapeutics, a Subsidiary of Celgene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06297226 | Mar 2024 → Jun 2027 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06615479 | Mar 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arlocabtagene Autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06297226 ↗ |
| Known as | Arlocabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068435 ↗ |
| Known as | BMS-986393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06121843 ↗ |
| Known as | CC-95266 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674813 ↗ |
| Modality | Cell therapy | “GPRC5D-directed CAR T Cell Therapy” NCT06297226 ↗ |
| Target | GPRC5D | “GPRC5D-directed CAR T Cell Therapy” NCT06297226 ↗ |